ELVN earnings analysis
What we found in ELVN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Enliven Therapeutics reported a net loss of $23.6 million for Q1 2026, an improvement from a loss of $28.5 million in the prior year, translating to a diluted EPS of -$0.38 compared to -$0.57 a year prior. Despite a continuation of negative cash flows from operations, the company reduced R&D expenses significantly to $20.7 million from $24.9 million year-over-year.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improvement in EPS
- Diluted EPS improved to -$0.38 from -$0.57 year-over-year.
- Reduced R&D Expenses
- R&D expenses decreased to $20.7 million compared to $24.9 million in Q1 2025.
- Increased Cash Position
- Cash, cash equivalents and marketable securities reached $452.4 million as of March 31, 2026.
- Rise in Other Income
- Other income increased to $4.2 million from $3.1 million the previous year.
- Decrease in Total Operating Expenses
- Total operating expenses fell to $27.8 million compared to $31.7 million in Q1 2025.
- Strong Liquidity Position
- Existing cash and marketable securities sufficient to fund operations into 2029.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continuing Negative Cash Flow
- Q1 2026 reported cash used in operations of $19.3 million, down from $24.1 million in Q1 2025.
- High Dependency on ELVN-001
- Company significantly relies on successful development and commercialization of ELVN-001.
- Potential for Future Funding Needs
- Substantial additional capital required for ongoing developments and operations, raising risk of dilution.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.38
What they said about what is next.
No numeric revenue or EPS guidance provided; improvements are anticipated with ongoing developments.
The filing reads better than the one before it.
What came before.
- 10-K · March 3, 2026
- Enliven is a clinical-stage small-molecule biopharma focused on ELVN-001 (BCR-ABL TKI). The 10-K highlights encouraging Phase 1/1b efficacy and tolerability data (MMR and DMR rates) and a plan to initiate a 2L+ Phase 3…
- 10-Q · November 12, 2025
- Enliven reported Q3 2025 net loss of $20,148,000 (EPS $(0.32)), an improvement from Q3 2024 net loss of $23,156,000 (EPS $(0.48)). The quarter saw lower total operating expenses of $25,096,000 (down from $27,068,000)…
- 10-K · March 13, 2025
- Enliven is a chemistry-led, clinical-stage oncology company advancing two lead small-molecule programs (ELVN-001 for BCR‑ABL/CML and ELVN-002 for HER2-driven cancers) with encouraging early-stage clinical signals. The…
- 10-Q · November 13, 2024
- Enliven reported a Q3 net loss of $23,156,000 (EPS $(0.48)), compared with a net loss of $20,769,000 (EPS $(0.51)) in Q3 2023; operating expenses rose to $27,068,000 from $24,248,000. The company ended the quarter with…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ELVN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever